PSP Research LLC — 13F Holdings & Portfolio
CIK 2106939 · latest 13F-HR filed 2026-07-09
PSP Research LLC manages $187.9M in 13F-reported U.S. long-equity assets across 75 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are XBI (48.01%), SGOV (37.51%), RPRX (0.33%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions, exited 15, added to 29, and trimmed 24.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
LAS VEGAS, NV 89138
$187.9M
Long-equity book
75
Distinct positions
2026-06-30
Filed 2026-07-09
+11 / −15 / ↑29 / ↓24
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- SPDR SERIES TRUST$53.8M +147.9%
- TREVI THERAPEUTICS INC$201.6K +56.3%
- NURIX THERAPEUTICS INC$161.7K +36.3%
- RAPPORT THERAPEUTICS INC$145.3K +33.2%
- ARGENX SE$126.6K +27.0%
Top Trims
- AXSOME THERAPEUTICS INC.-$236.1K -49.1%
- BRIDGEBIO PHARMA INC-$222.1K -49.9%
- DEFINIUM THERAPEUTICS INC-$187.3K -28.5%
- CRISPR THERAPEUTICS AG-$179.2K -39.7%
- DIANTHUS THERAPEUTICS INC-$175.9K -41.9%
New Positions
- ASCENDIS PHARMA A/S$400.1K
- LIQUIDIA CORPORATION$398.6K
- KRYSTAL BIOTECH INC$257.2K
- ARRIVENT BIOPHARMA INC$244.6K
- JAZZ PHARMACEUTICALS PLC$234.0K
Exited Positions
- SERA PROGNOSTICS INC$4.9M
- TYRA BIOSCIENCES INC$612.8K
- ASCENDIS PHARMA A/S$571.8K
- CYTOKINETICS INC$547.1K
- AGIOS PHARMACEUTICALS INC$507.4K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SPDR SERIES TRUST | XBI | 78464A870 | $90.2M | 48.01% | 570,000 | SH |
| 2 | ISHARES TR | SGOV | 46436E718 | $70.5M | 37.51% | 700,000 | SH |
| 3 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $616.8K | 0.33% | 11,000 | SH |
| 4 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $606.5K | 0.32% | 25,000 | SH |
| 5 | INCYTE CORP | INCY | 45337C102 | $600.8K | 0.32% | 5,300 | SH |
| 6 | ARGENX SE | ARGX | 04016X101 | $594.7K | 0.32% | 641 | SH |
| 7 | DISC MEDICINE INC | IRON | 254604101 | $585.1K | 0.31% | 8,000 | SH |
| 8 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $583.4K | 0.31% | 14,000 | SH |
| 9 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $567.6K | 0.30% | 17,000 | SH |
| 10 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $559.5K | 0.30% | 30,000 | SH |
| 11 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $556.6K | 0.30% | 23,000 | SH |
| 12 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $549.4K | 0.29% | 10,000 | SH |
| 13 | HALOZYME THERAPEUTICS INC | HALO | 40637H109 | $547.9K | 0.29% | 7,000 | SH |
| 14 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $539.2K | 0.29% | 6,800 | SH |
| 15 | PHARVARIS N V | PHVS | N69605108 | $518.7K | 0.28% | 15,000 | SH |
| 16 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $516.5K | 0.27% | 19,700 | SH |
| 17 | AURINIA PHARMACEUTICALS INC | AUPH | 05156V102 | $509.1K | 0.27% | 30,000 | SH |
| 18 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $505.6K | 0.27% | 3,000 | SH |
| 19 | IMMUNOVANT INC | IMVT | 45258J102 | $500.9K | 0.27% | 13,000 | SH |
| 20 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $500.1K | 0.27% | 19,766 | SH |
| 21 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $489.4K | 0.26% | 6,000 | SH |
| 22 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $483.7K | 0.26% | 13,000 | SH |
| 23 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $480.7K | 0.26% | 15,141 | SH |
| 24 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $470.4K | 0.25% | 10,000 | SH |
| 25 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $464.4K | 0.25% | 12,000 | SH |
| 26 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $458.7K | 0.24% | 4,000 | SH |
| 27 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $444.2K | 0.24% | 20,000 | SH |
| 28 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $441.0K | 0.23% | 1,465 | SH |
| 29 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $440.6K | 0.23% | 7,000 | SH |
| 30 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $437.2K | 0.23% | 20,000 | SH |
| 31 | EXELIXIS INC | EXEL | 30161Q104 | $435.3K | 0.23% | 8,000 | SH |
| 32 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $411.6K | 0.22% | 11,000 | SH |
| 33 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $406.7K | 0.22% | 12,000 | SH |
| 34 | ASCENDIS PHARMA A/S | ASND | K08588103 | $400.1K | 0.21% | 1,500 | SH |
| 35 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $398.6K | 0.21% | 5,000 | SH |
| 36 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $392.6K | 0.21% | 12,000 | SH |
| 37 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $390.1K | 0.21% | 10,000 | SH |
| 38 | IMMUNOME INC | IMNM | 45257U108 | $381.4K | 0.20% | 18,000 | SH |
| 39 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $367.7K | 0.20% | 3,000 | SH |
| 40 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $364.1K | 0.19% | 10,000 | SH |
| 41 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $355.2K | 0.19% | 7,000 | SH |
| 42 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $355.1K | 0.19% | 4,000 | SH |
| 43 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $338.4K | 0.18% | 20,000 | SH |
| 44 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $322.2K | 0.17% | 600 | SH |
| 45 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $319.8K | 0.17% | 5,000 | SH |
| 46 | ALKERMES PLC | ALKS | G01767105 | $314.4K | 0.17% | 6,000 | SH |
| 47 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $312.6K | 0.17% | 10,000 | SH |
| 48 | ARDELYX INC | ARDX | 039697107 | $306.0K | 0.16% | 60,000 | SH |
| 49 | VERA THERAPEUTICS INC | VERA | 92337R101 | $300.4K | 0.16% | 7,000 | SH |
| 50 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $292.7K | 0.16% | 2,500 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-07-09 | $187.9M | 75 | 0001951757-26-000944 |
| 2026-03-31 | 2026-04-17 | $141.3M | 79 | 0001951757-26-000630 |
| 2025-12-31 | 2026-02-06 | $114.4M | 85 | 0001951757-26-000380 |